The significance of the homozygous CYP2A6 deletion on nicotine metabolism:: A new genotyping method of CYP2A6 using a single PCR-RFLP

被引:65
作者
Kitagawa, K
Kunugita, N
Katoh, T
Yang, MH
Kawamoto, T
机构
[1] Univ Occupat & Environm Hlth, Dept Environm Hlth, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan
[2] Univ Occupat & Environm Hlth, Sch Hlth Sci, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan
关键词
D O I
10.1006/bbrc.1999.1182
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A convenient and specific CYP2A6 genotyping method was developed in this study. This method consisting of a single PCR-RFLP is capable of resolving the genotype into either CYP2A6*1 (wild type), CYP2A6*2, or CYP2A6*3. Among 252 Japanese persons genotyped, 241 were genotyped as the wild type, 1 as an unknown variant, and none as either CYP2A6*2 or CYP2A6*3. A homozygous deletion was found in the 10 remaining subjects. To clarify the metabolic significance of this deletion in the whole human body, urinary cotinine, the principal metabolite of nicotine, was analyzed subsequent to smoking. Cumulated urinary cotinine excretion in the homozygously CYP2A6-deleted individuals was about one-seventh compared to the control group (wild type). This study provides a firm experimental basis for correlating genotypic characterization of CYP2A6 with phenotypic expression of nicotine metabolism. (C) 1999 Academic Press.
引用
收藏
页码:146 / 151
页数:6
相关论文
共 31 条
  • [1] 5 OF 12 FORMS OF VACCINIA VIRUS-EXPRESSED HUMAN HEPATIC CYTOCHROME-P450 METABOLICALLY ACTIVATE AFLATOXIN-B1
    AOYAMA, T
    YAMANO, S
    GUZELIAN, PS
    GELBOIN, HV
    GONZALEZ, FJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (12) : 4790 - 4793
  • [2] DEFICIENT C-OXIDATION OF NICOTINE
    BENOWITZ, NL
    JACOB, P
    SACHS, DPL
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (05) : 590 - 594
  • [3] A TOBACCO SMOKE-DERIVED NITROSAMINE, 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE, IS ACTIVATED BY MULTIPLE HUMAN CYTOCHROME P450S INCLUDING THE POLYMORPHIC HUMAN CYTOCHROME P4502D6
    CRESPI, CL
    PENMAN, BW
    GELBOIN, HV
    GONZALEZ, FJ
    [J]. CARCINOGENESIS, 1991, 12 (07) : 1197 - 1201
  • [4] Nomenclature for human CYP2D6 alleles
    Daly, AK
    Brockmoller, J
    Broly, F
    Eichelbaum, M
    Evans, WE
    Gonzalez, FJ
    Huang, JD
    Idle, JR
    IngelmanSundberg, M
    Ishizaki, T
    JacqzAigrain, E
    Meyer, UA
    Nebert, DW
    Steen, VM
    Wolf, CR
    Zanger, UM
    [J]. PHARMACOGENETICS, 1996, 6 (03): : 193 - 201
  • [5] DEFECTIVE N-OXIDATION OF SPARTEINE IN MAN - NEW PHARMACOGENETIC DEFECT
    EICHELBAUM, M
    SPANNBRUCKER, N
    STEINCKE, B
    DENGLER, HJ
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 16 (03) : 183 - 187
  • [6] FERNANDEZSALGUERO P, 1995, AM J HUM GENET, V57, P651
  • [7] PCR AMPLIFICATION FROM PARAFFIN-EMBEDDED TISSUES - EFFECTS OF FIXATIVE AND FIXATION TIME
    GREER, CE
    PETERSON, SL
    KIVIAT, NB
    MANOS, MM
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1991, 95 (02) : 117 - 124
  • [8] CYP2A6 gene polymorphism and risk of liver cancer and cirrhosis
    Gullsten, H
    Agundez, JAG
    Benitez, J
    Laara, E
    Ladero, JM
    DiazRubio, M
    FernandezSalguero, P
    Gonzalez, F
    Rautio, A
    Pelkonen, O
    Raunio, H
    [J]. PHARMACOGENETICS, 1997, 7 (03): : 247 - 250
  • [9] Variability of coumarin 7- and 3-hydroxylation in a Jordanian population is suggestive of a functional polymorphism in cytochrome P450 CYP2A6
    Hadidi, H
    Irshaid, Y
    Vågbo, CB
    Brunsvik, A
    Cholerton, S
    Zahlsen, K
    Idle, JR
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (05) : 437 - 441
  • [10] Hoffman SMG, 1995, J MOL EVOL, V41, P894